Back to Results

LTE Study

Title A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants with Vitiligo (TRuE LTE)
Therapeutic Area Vitiligo
Principal Investigator David Rosmarin, MD
Min Age 12 Years
Max Age 75 Years
Gender Any
Contact Nicole Dumont
617-636-7462
ndonovan1@tuftsmedicalcenter.org
More Information https://clinicaltrials.gov/ct2/show/NCT04530344

Overview

The purpose of this study is to continue to assess the effect and safety of ruxolitinib cream on people and their vitiligo with long-term use and also to assess how long the effect lasts on people who stop using ruxolitinib cream.

Study Details

Inclusion Criteria

This Study is an extension from the Parent Study you have to have been enrolled in (Study INCB 18424-306 or Study INCB 18424-307).  

Exclusion Criteria

This Study is an extension from the Parent Study you have to have been enrolled in (Study INCB 18424-306 or Study INCB 18424-307).  

Study Requirements

Study length is approximately 1 year.